



October 8 - 10, 2025
Belgrade, Serbia

SCIENTIFIC PROGRAMME

WEDNESDAY, OCTOBER 08, 2025

12.00 – 13.00 Registration and Networking over light lunch

13.00 – 13.20 Opening Ceremony

Prof. Sonja Levanat, *HDIR President*

Prof. Engin Ulukaya, *MOKAD President*

Dr Milena Čavić, *SDIR President*

Minister of Health of the Republic of Serbia

Minister of Science, Technological Development, and Innovation of the Republic of Serbia

Ass. Prof. Milan Žegarac, *Acting Director of the Institute for Oncology and Radiology of Serbia*

Dr Mirjana Mihailović, *Director of the Institute for Biological Research "Siniša Stanković", University of Belgrade, Serbia*

Danijela Vučićević, *Acting Director of the Center for the Promotion of Science, Republic of Serbia*

Dr Milica Pešić, Dr Neda Slade, Dr Sergi Castellvi-Bel, *SHM1RC Scientific Committee Chairs*

Dr Ana Damjanović Veličković, Dr Petar Ozretić, *SHM1RC Organizing Committee Chairs*

13.20 – 14.30 Session 1: Benefits of Combination Therapies in Cancer Treatment

Chairs: Ivana Matić and Vesna Vučić

Invited Lecture 1

Orcun Can (Turkey), Department of Medical Oncology, Acibadem Maslak Hospital, Istanbul

Benefits of Combination Therapies in Cancer Treatment (15')

Discussion 5'

Invited Lecture 2

Katalin Hideghéty (Hungary), Department of Oncotherapy at the University of Szeged
Novel Approaches in Radiation Oncology with a Special Focus on Combination Therapies (15')

Discussion 5'

Invited Lecture 3

Zorica Cvetković (Serbia), Clinical Hospital Center Zemun, Faculty of Medicine, University of Belgrade

Benefits of combination therapies in the treatment of haematological malignancies (15')

Discussion 5'

Short presentations selected from abstracts

Beyza Öztürk Sever (Turkey), *Investigation of the effect of exportin-1 gene inhibition with selinexor on glioma (5')*

Alexey Bogdanov (Russia), *Overcoming oxygen heterogeneity in cancer photodynamic therapy to boost cytotoxicity (5')*

Discussion 5'

14.30 – 15.40 Session 2: Personalized Anticancer Treatment through Targeting Signaling Pathways

Chairs: Neda Slade and Ana Đurić

Invited Lecture 1

Omer Faruk Bayrak (Turkey), Yeditepe University, Istanbul

The Critical Role of Tumor Typing in Cancer Treatment and the Expanding Horizons of Molecular Oncology (15')

Discussion 5'

Invited Lecture 2

Anamaria Brozović (Croatia), Ruđer Bošković Institute, Zagreb

Manipulation of genes involved in both drug resistance and drug-induced EMT reveals unpredictable ovarian cancer cell morphology and stress (15')

Discussion 5'

Invited Lecture 3

Nevena Gajović (Serbia), Faculty of Medical Sciences, Kragujevac

The role of antidiabetics on growth and progression of breast cancer by modulating antitumor immunity (15')

Discussion 5'

Short presentations selected from abstracts

Ena Šimunić (Croatia), *Foxo3a mediates Sirt3-dependent regulation of ERα signaling in MCF-7 breast cancer cells (5')*

Mumin Alper Erdogan (Turkey), *Silencing of Nav1.7 voltage-gated sodium channel by siRNA modulates oncogenic pathways in pancreatic cancer (5')*

Discussion 5'

15.40 – 16.00 Vivogen Sponsored Symposium

Jelena Grujović (Serbia), *Genexus™ Integrated Next Generation Sequencer in Oncology Research and Diagnostics*

16.00 – 17.00 Coffee break & Poster Session 1 & Projects Hub

17.00 – 17.50 Session 3: Tumor Microenvironment - Friend or Foe

Chairs: Jelena Grahovac and Andrei Turtoi

Invited Lecture 1

Andrei Turtoi (France), National Institute of Health and Medical Research, Montpellier
Cancer-associated fibroblast spatial heterogeneity (15')

Discussion 5'

Invited Lecture 2

Lazar Vujanović (USA), University of Pittsburgh, PA
Immune cell dynamics associate with response to neoadjuvant cancer immunotherapies (15')

Discussion 5'

Short presentations selected from abstracts

Tommy Chastel (France), *Role of Eicosanoid Receptor in Stroma – Cancer Communication(5')*

Discussion 5'

**Second presentation rescheduled to Session 13*

17.50 – 18.10 Labena Sponsored Symposium

Uršula Prosenc Zmrzljak (SLO), *Prospect for the future: better diagnostics of liver cancer with the use of Xenium spatial transcriptomics*

18.10 – 19.00 Session 4: Immunooncology

Chairs: Ana Vuletić and Milica Perišić Nanut

Invited Lecture 1

Ivan Jovanović (Serbia), Faculty of Medical Sciences, Kragujevac

Dual blockage of PD-L/PD-1 and IL33/ST2 axes as a potential antitumor therapy (15')

Discussion 5'

Invited Lecture 2

Milica Perišić Nanut (Slovenia), Jozef Stefan Institute, Ljubljana

Immune Checkpoint Inhibition Alters Cystatin F Expression in CTLs of Melanoma Patients (15')

Discussion 5'

Short presentations selected from abstracts

Nikita Volkov (Russia), *Integrated Clinical, Molecular, Microbiome, and Radiomic Profiling to Improve Immunotherapy Response Prediction in Inoperable NSCLC (5')*

Discussion 5'

19.00 – 19.30 Day One Conclusion & Networking

THURSDAY, OCTOBER 09, 2025

09.00 – 10.15 Session 5: Exploring the Role of MDR Mechanisms and Stem Cell Biology in Cancer and Cancer Treatment Strategies

Chairs: Jelena Milašin and Gergely Szakacs

Invited Lecture 1

Katalin Goda (Hungary), University of Debrecen, Debrecen

Multidrug resistance - poly-specific drug recognition by ABC transporters (15')

Discussion 5'

Invited Lecture 2

Miloš Lazarević (Serbia), School of Dental Medicine, University of Belgrade

Eliminating Oral Cancer Stem Cells by Targeting Oncogenic miR-21 and BET-Mediated Transcription (15')

Discussion 5'

Invited Lecture 3

Tanja Matijević Glavan (Croatia), Rudjer Boskovic Institute, Zagreb

The role of ufmylation in head and neck cancer stem cells (15')

Discussion 5'

Short presentations selected from abstracts

Janja Josić (Croatia), *Expression profiling of p53 family isoforms in targeted therapy-resistant primary melanoma cell lines* (5')

Muhlis Akman (Turkey), *TFEB Controls Chemoresistance in NSCLC* (5')

Discussion 5'

10.15 – 11.10 Session 6: Cancer Epidemiology: Strategies for Prevention and Early Detection

Chairs: Ana Krivokuća and Sergi Castellvi-Bel

Invited Lecture 1

Sergi Castellvi-Bel (Spain), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona

Genetic predisposition to gastrointestinal cancer (15')

Discussion 5'

Invited Lecture 2

Ivana Božović Spasojević (Serbia), Institute for Oncology and Radiology of Serbia, Belgrade

Adjuvant therapy options for patients with germline BRCA1/2 mutations (15')

Discussion 5'

Short presentations selected from abstracts

Jasmina Obradović (Serbia), *Distribution of EGFR -216G/T (rs712829) polymorphism: Implications for cancer risk and pharmacogenomics* (5')

Katarina Zeljić (Serbia), *Identification and characterization of microRNAs involved in the progression from normal oral mucosa to oral cancer* (5')

Discussion 5'

11.10 – 12.00 Coffee break & Poster Session 2 & Projects Hub

12.00 – 12.20 AlfaGenetics Sponsored Symposium

Bojana Cikota Aleksić (Serbia) & Ana Damjanović Veličković (Serbia)

Advancing Precision Oncology: Integrating Easy2 - Automated Nucleic Acid Extraction and QIAcuity Digital PCR Solutions by QIAGEN

12.20 – 13.10 Session 7: Advancements in Molecular Diagnostics and Cancer Biomarkers in Oncology

Chairs: Radmila Janković, Vesna Ćorić, and Petar Ozretić

Invited Lecture 1

Vesna Musani (Croatia), Rudjer Boskovic Institute, Zagreb

The (first) 20 years of BRCA testing in Croatia (15')

Discussion 5'

Invited Lecture 2

Marijana Milović Kovačević (Serbia), Institute for Oncology and Radiology of Serbia, Belgrade

Homologous recombination deficiency-based therapeutic strategies in ovarian cancer (15')

Discussion 5'

Short presentations selected from abstracts

Katarina Živić (Serbia), *HRD testing doubled the number of ovarian cancer patients eligible for PARP inhibitor therapy (5')*

Discussion 5'

13.10 – 13.30 ELTA MS90 Sponsored Symposium

Jadranka Antić (Serbia), *Genetic basis of adrenocortical tumors - Can it be detected without Next-Generation Sequencing?*

Ivana Milićević (Serbia), *Genetic basis of pancreatic, pituitary and parathyroid glands tumors - Can it be detected without Next-Generation Sequencing?*

13.30 – 14.30 Lunch

14.30 – 15.35 Session 8: Liquid Biopsy (EACR Plenary Session)

Chairs: Evi Lianidou, Milena Čavić and Mladen Marinković

Plenary Lecture 1

Evi Lianidou (EACR), National and Kapodistrian University of Athens, Greece

The potential of comprehensive liquid biopsy analysis for the management of cancer patients (25')

Discussion 10'

Invited Lecture

Berkcan Dogan (Turkey), Bursa Uludag University, Bursa

Novel miRNA Signatures as Potential Biomarkers for Circulating Tumor Cell Status in Metastatic Colorectal Cancer (15')

Discussion 5'

Short presentations selected from abstracts

Miodrag Vuković (Serbia), *The use of pleural effusion from patients with lung cancer as a source of extracellular vesicles – first report from the EXPAND-EV project (5')*
Discussion 5'

15.35 – 15.55 Altium Sponsored Symposium

Milorad Ivetić & Luka Bačkonja (Serbia)

If you only had 24 hours, what would you discover?

15.55 – 17.10 Session 9: Clinical Oncology - Bridging Patients and Researchers

Chairs: Jelena Spasić and Bojana Cikota-Aleksić

Plenary Lecture 2

Karen-Lise Garm-Spindler (Denmark), Aarhus University Hospital, Aarhus University
ctDNA-Response evaluation criteria in solid tumors - significance for monitoring of patient outcomes (25')

Discussion 10'

Short presentations selected from abstracts

Valentina Karadžić (Serbia), *Germline BRCA1 and BRCA2 Testing in the Context of Personalized Therapy: National Experience from Serbia in Breast Cancer Management (5')*
Discussion 5'

Patient-clinician-scientist educational interactive panel (30')

Siniša Varga (Croatian Health Insurance Fund), *Bridging Cancer Care and Research Gaps in Croatia: The CORN-CCI4EU Deep Dive (10')*

Siniša Varga (Croatian Health Insurance Fund), Engin Ulukaya (Turkey), Mirjana Branković-Magić (Europa Donna), Vesna Bondžić (Women Center Milica), Karen-Lise Garm-Spindler (Aarhus University Hospital, Denmark), Savo Pilipović (Serbian Patients Association), Zorana Maravić (Digestive Cancers Europe)

17.10– 18.10 Coffee break & Poster Session 3 & Projects Hub

18.10 – 19.30 Meet the Experts

Chairs: Katarina Zeljić and Aleksandra Nikolić

19.30 Day Two Conclusion

20.30 CONGRESS DINNER

FRIDAY, OCTOBER 10, 2025

09.00 – 10.15 Session 10: Bioinformatics and Cancer Genomics

Chairs: Thomas Mohr, Nina Petrović, and Ömer Faruk Bayrak

Invited Lecture 1

Sema Misir (Turkey), Department of Biochemistry, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas

CircRNA-miRNA interactions and bioinformatics analysis in cancer (15')

Discussion 5'

Invited Lecture 2

Verena Paulitschke (Austria), Medical University of Vienna

Proteomic and metabolomics profiling of advanced melanoma patients to predict and monitor the therapeutic response to immune therapy (15')

Discussion 5'

Invited Lecture 3

Miodrag Dragoj (Serbia), Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade

Personalized Genomic Analysis for Clinical Insights in Non-Small Cell Lung Cancer (15')

Discussion 5'

Short presentations selected from abstracts

Aleksandra Bibić (Serbia), *Comparative analysis of machine learning algorithm results in predicting the probability of rectal tumor presence (5')*

Işıl Özdemir (Turkey), *Comprehensive analysis of lysyl oxidase family gene expression and prognostic significance in colorectal cancer (5')*

Discussion 5'

10.15 – 11.30 Session 11: Novel Cancer Therapies and Drug Development Strategies

Chairs: Konstantinos Dimas and Aleksandra Nikolić

Invited Lecture 1

Árpád Szöör (Hungary), University of Debrecen

CART cell therapy: a global perspective with a focus on Hungary's journey (15')

Discussion 5'

Invited Lecture 2

Marijeta Kralj (Croatia), Ruđer Bošković Institute, Zagreb

Targeting Multidrug Resistance and Cancer Stem Cells with Ionophores (15')

Discussion 5'

Invited Lecture 3

Dijana Bovan (Serbia), Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade

Dual targeting concept: hybrid molecules of cisplatin and anti-inflammatory drugs (15')

Discussion 5'

Short presentations selected from abstracts

Ema Lupšić (Serbia), *Adamantane–sclareol hybrids selectively target multidrug resistant glioblastoma cells by inducing oxidative stress (5')*

Vuk Gordić (Serbia), *The effects of novel diclofenac-based carborane-substituted prodrug on colon cancer cell lines and mouse-derived organoids (5')*

Discussion 5'

11.30 – 12.30 Coffee break & Poster Session 4 & Projects Hub

12.30 – 13.20 Session 12: Toxic Triggers: Environmental Chemicals and Cancer Risk

Chairs: Aleksandra Buha Djordjevic and Serap Celikler

Invited Lecture 1

Aysegül Çebi (Turkey), Faculty of Health Sciences, Giresun University

Acrylamide in food and its carcinogenic potential: What do we really know? (15')

Discussion 5'

Invited Lecture 2

Janoš Terzić (Croatia), University of Split, School of Medicine

Role of microbiota in bladder carcinogenesis (15')

Discussion 5'

Short presentation selected from abstracts of Session 3

Milica Jakšić Karišik (Serbia), *Exosomes as Key Mediators of Fibroblast Reprogramming into CAFs via Oncogenic miRNA Transfer and Activation of Cancer-Related Pathways (5')*

Discussion 5'

13.30 – 14.30 Lunch

14.30 – 15.45 Session 13: Tumor Metabolism

Chairs: Sandra Sobočanec, Busra Kose Demirtas and Alexey Bogdanov

Invited Lecture 1

Büşra Kose Demirtas (Turkey), Medical Faculty, Istinye University, Istanbul

Tumor metabolism in the picture: tracing and visualizing the metabolic alterations in cancer (15')

Discussion 5'

Invited Lecture 2

Alexey Bogdanov (Russia), Oncocentre GBUZ "SPb KNTsSVMP(o) named after N.P. Napalkova"

Changes in tumor metabolism, consequences, and therapeutic opportunities (15')

Discussion 5'

Invited Lecture 3

Ana Čipak Gašparović (Croatia), Ruđer Bošković Institute, Zagreb

Interplay between redox regulation and cancer metabolism (15')

Discussion 5'

Short presentations selected from abstracts

Milica Kosić (Serbia), *Mechanistic insights into synergistic antimelanoma activity of glycolysis inhibition and lysosomal destabilization (5')*

Drenka Trivanović (Serbia), *Targeting metabolic vulnerabilities in multiple myeloma: The role of NAD⁺ depletion and bone marrow adipose tissue (5')*

Discussion 5'

15.45 – 17.00 Session 14: Innovative Models and Approaches in Cancer Research

Chairs: Maja Sabol, Sedef Ziyank, and Danijela Maksimović-Ivanić

Invited Lecture 1

Inga Urić (Croatia), University of Zagreb, Faculty of Science

Tracking Osteosarcoma Progression: A Longitudinal Single-Patient Study Integrating Functional Analyses and Single-Cell Transcriptom (15')

Discussion 5'

Invited Lecture 2

Ivan Ranđelović (Hungary), National Institute of Oncology, Budapest

Bridging the Gap: The Role of PDTX Models in Cancer Therapy Development (15')

Discussion 5'

Invited Lecture 3

Melita Vidaković (Serbia), Institute for Biological Research “Siniša Stanković” - National Institute of Republic of Serbia, University of Belgrade

Targeted rewriting of epigenetic markers as a new therapeutic approach in triple negative breast cancer (15')

Discussion 5'

Short presentations selected from abstracts

Jasmina Stojkovska (Serbia), *Bridging the in vitro–in vivo gap: Tumor engineering for relevant and reliable cancer research (5')*

Isidora Petrović (Serbia), *Modelling pancreatic carcinoma in vitro- critical morphological and functional differences between 2D and 3D mono- and co-cultures (5')*

Discussion 5'

16.45 – 17.10 Coffee break & Projects Hub

17.10 – 17.30 Roche Sponsored Symposium

Branka Zukić (Serbia), *Comprehensive Approaches in Molecular Oncology: Avenio In-house Testing and FMI Liquid Biopsy Services*

17.30 – 19.00 Session 15: Strengthening Regional Collaboration

Chairs: Milica Pešić, Sonja Levanat and Makis Zoidakis

Invited Lecture 1

Engin Ulukaya (Turkey), Medical Faculty, Istinye University, Istanbul

Palladium-based anticancer compounds in cancer treatment: A new hope or not? (15')

Discussion 5'

Invited Lecture 2

Sandra Sobočanec (Croatia), Ruđer Bošković Institute, Zagreb

From Tumor Suppression to Stress Response: The Diverse Roles of Sirtuin 3 in Cancer and Sex-Dependent DNA Damage Adaptation (15')

Discussion 5'

Invited Lecture 3

Ivana Matić (Serbia), Institute for Oncology and Radiology of Serbia

Investigation of individual radiosensitivity of prostate cancer patients under radiation treatment (15')

Discussion 5'

Interactive panel on regional collaboration (30')

Sonja Levanat (HDIR President), Engin Ulukaya (MOKAD President), Milena Čavić (SDIR President), Evi Lianidou (Greece), Ivan Randelović (Hungary), Katalin Goda (Hungary), Katalin Hideghéty (Hungary), Gergely Szakacs (Austria), Alexey Bogdanov (Russia), Konstantinos Dimas (Greece), Árpád Szöőr (Hungary), Muhlis Akman (Turkey), Sema Misir (Turkey), Petar Ozretić (Croatia), Neda Slade (Croatia), Anamaria Brozović (Croatia), Ana Čipak-Gašparović (Croatia)

19.00 Award Ceremony

EACR-sponsored Best Abstract Awards

FEBSOpenBio-sponsored Best Abstract Award


Molecular Oncology Journal-sponsored Best Short Presentation Award

ELBS-sponsored Best Abstract Award

19.30 Congress conclusions & networking

SATURDAY, OCTOBER 11, 2025

11.00 – 14.00 GUIDED TOUR



SPONSORED AND SUPPORTED BY A VAST FAMILY OF SOCIALLY RESPONSIBLE ENTITIES AND COMPANIES:



**INSTITUT ZA ONKOLOGIJU
I RADIOLOGIJU SRBIJE**

Institute for Oncology and Radiology of Serbia



Institute for Biological Research "Siniša Stanković" - National Institute of the Republic of Serbia, University of Belgrade



Ministry of Science, Technological Development, and Innovation of the Republic of Serbia and Ministry of Health of the Republic of Serbia

EACR

European Association
for Cancer Research

European Association for Cancer Research



Federation of European Biochemical Societies

**Molecular
Oncology**

Molecular Oncology Journal



European Liquid Biopsy Society



NATIONAL TOURISM ORGANISATION of SERBIA

PLATINUM SPONSOR



GOLD SPONSORS



SILVER SPONSORS



SPONSORS



SPONSORS

SUPERLAB[®]
Your lab – Our passion



This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There is no text or other markings on the paper.

[illegible]